- Migraine Canada - https://migrainecanada.org -

CGRP antibodies: practical details on access

 

We need better options for migraine [1] prevention. And, thanks to the persistent researchers who worked so hard on CGRP, we now have a new class of medications, CGRP antibodies. Below is a table of the drugs with the doses, the brand names, and the status in Canada. The three products are currently available in the USA. Another product, eptinezumab, is not yet available in the USA and is not planned to come to Canada.

 

  Erenumab

 

APPROVED IN CANADA since December 2018

Galcanezumab

 

NOT YET APPROVED IN CANADA

Fremanezumab

 

NOT YET APPROVED IN CANADA

Brand Name Aimovig Emgality Ajovy
Target of the antibody CGRP receptor CGRP itself CGRP itself
Dose 70 mg monthly or

 

140 mg monthly Auto-injector

240 mg first dose

 

120 mg monthly

Auto-injector

225 mg monthly or

 

675 mg quarterly

Syringe

Access Aimovig GO program covers until coverage by insurance settled To be determined To be determined
Tested for episodic migraine? Yes Yes Yes
Tested for chronic migraine [2]? Yes Yes Yes
Tested for cluster headache? No Yes

 

Results to be published

Yes

 

Results to be published

 

A few comments on CRGP MABs [3] may be helpful, some applying specifically to Aimovig as it is the only one accessible in Canada for now:

Written by Dr Elizabeth Leroux, April 2019